Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$190.85
+0.7%
$184.22
$163.33
$251.99
$54.75B0.272.61 million shs657,760 shs
DexCom, Inc. stock logo
DXCM
DexCom
$80.58
+2.1%
$81.78
$57.52
$93.25
$31.60B1.483.92 million shs3.08 million shs
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$80.81
-0.5%
$78.63
$64.00
$83.00
$47.37B1.074.46 million shs1.36 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$640.82
+1.1%
$588.74
$356.14
$688.12
$51.24B1.56705,168 shs220,741 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+0.65%-3.16%+5.78%+10.89%-21.83%
DexCom, Inc. stock logo
DXCM
DexCom
+6.22%+3.33%+3.50%-7.95%+9.07%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
-0.62%+0.30%+1.46%+4.56%+18.18%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
-0.86%-1.08%-7.15%+21.40%+35.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$190.85
+0.7%
$184.22
$163.33
$251.99
$54.75B0.272.61 million shs657,760 shs
DexCom, Inc. stock logo
DXCM
DexCom
$80.58
+2.1%
$81.78
$57.52
$93.25
$31.60B1.483.92 million shs3.08 million shs
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$80.81
-0.5%
$78.63
$64.00
$83.00
$47.37B1.074.46 million shs1.36 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$640.82
+1.1%
$588.74
$356.14
$688.12
$51.24B1.56705,168 shs220,741 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+0.65%-3.16%+5.78%+10.89%-21.83%
DexCom, Inc. stock logo
DXCM
DexCom
+6.22%+3.33%+3.50%-7.95%+9.07%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
-0.62%+0.30%+1.46%+4.56%+18.18%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
-0.86%-1.08%-7.15%+21.40%+35.17%
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.18B2.71$20.90 per share9.13$88.87 per share2.15
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B7.84$2.40 per share33.52$6.56 per share12.28
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$5.44B8.72$2.71 per share29.79$18.07 per share4.47
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.90B13.15$12.31 per share52.06$18.23 per share35.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.5634.3612.201.447.51%16.23%7.46%11/6/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.4455.9532.761.5813.29%30.41%10.08%10/23/2025 (Estimated)
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$4.17B$6.9511.6129.393.9272.96%15.01%11.56%10/23/2025 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$887.87M$12.0153.3347.194.1924.41%64.42%29.89%10/30/2025 (Estimated)

Latest DXCM, BDX, EW, and IDXX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q3 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.40$3.68+$0.28$1.99$5.50 billion$5.51 billion
8/4/2025Q2 2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.28$3.63+$0.35$3.63$1.06 billion$1.11 billion
7/30/2025Q2 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.45$0.48+$0.03$0.45$1.13 billion$1.16 billion
7/24/2025Q2 2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$0.62$0.67+$0.05$0.56$1.49 billion$1.53 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.18%N/A74.82%53 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A

Latest DXCM, BDX, EW, and IDXX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/22/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.29%9/8/20259/8/20259/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.69
1.10
0.62
DexCom, Inc. stock logo
DXCM
DexCom
0.48
1.52
1.35
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.06
4.68
3.87
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.31
1.11
0.79

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
79.46%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.34%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.98%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
74,000286.63 million285.60 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.15 million390.90 millionOptionable
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
15,800587.10 million585.10 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00080.00 million79.22 millionOptionable

Recent News About These Companies

Why Is Idexx (IDXX) Down 0.4% Since Last Earnings Report?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$190.85 +1.24 (+0.65%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

DexCom stock logo

DexCom NASDAQ:DXCM

$80.58 +1.66 (+2.10%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Edwards Lifesciences stock logo

Edwards Lifesciences NYSE:EW

$80.81 -0.41 (-0.50%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$640.82 +6.87 (+1.08%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.